The role of immune checkpoint inhibitor therapy in advanced adrenocortical carcinoma revisited: review of literature

摘要: Adrenocortical carcinoma (ACC) is a rare disease with few therapeutic options. There an urgency of new effective options for these patients. The role immune checkpoint inhibitors (ICI) in advanced ACC patients still unclear. We conducted MEDLINE search using the following string: adrenocortical and immunotherapy or inhibitors. found four case series comprising 10 patients, prospective studies totaling 115 response rate (RR) group was 1 complete response, 3 partial (PR), 4 stable (SD), 2 progressive (PD). median progression-free survival (mPFS) ranged from to 31 months overall (mOS) 4.3 31 months. results trials variable, PR 6 23%, SD 18 50% control 30 64%. mPFS reported varied 1.8 2.6 months while mOS 10.6 24.9 months. were five sustained more than 24 months. most common treatment-related adverse event (TRAE) increase liver enzymes. No deaths reported. Better terms RR observed that used pembrolizumab. predictive biomarker up now. ICI, mainly pembrolizumab, potential option, which safe associated prolonged OS benefit, selected ACC.